LUCID CAPITAL MARKETS Initiates Coverage On Insight Molecular with Buy Rating, Announces Price Target of $8

Benzinga · 3d ago
LUCID CAPITAL MARKETS analyst Alex Nowark initiates coverage on Insight Molecular (NASDAQ:IMDX) with a Buy rating and announces Price Target of $8.